Psychedelics Research

In a recent conversation on The Joe Rogan Experience, Elon Musk and Joe Rogan delivered a sharp critique of the pharmaceutical industry, bashing its history of prioritizing profit over public safety. Their discussion not only touched on well-known scandals like OxyContin and Vioxx but also ventured...

A new study published in AJOB Neuroscience reveals that most Americans are supportive of psilocybin use, a psychedelic compound derived from "magic mushrooms," in supervised, licensed settings. As PsyPost reported, this approval, spanning across political lines, underscores public openness to the...

Compass Pathways (NASDAQ:CMPS) has announced delays for two key Phase 3 clinical trials involving its psilocybin program, widely seen as a leader in the psychedelic drug development space. As Endpoint News reported, the unexpected timeline shifts, unveiled in the company's third-quarter earnings...

Federal agencies recently convened in a pivotal public meeting, hosted by the Reagan-Udall Foundation for the U.S. Food and Drug Administration (FDA), to discuss emerging treatments for post-traumatic stress disorder (PTSD), with a focus on the potential of psychedelics. As Lexology reported, the...

In a groundbreaking study published in Neuron, researchers at Johns Hopkins University uncovered how the psychedelic drug DOI (2,5-dimethoxy-4-iodoamphetamine) reduces anxiety by activating particular neurons in the brain. The research looks at a specific type of brain cell called parvalbumin-...

A recent study published in the Journal of Psychopharmacology sheds new light on how DMT, a powerful psychedelic, could impact both mental and physical well-being. The study found that profound, mystical experiences often reported by DMT users are closely linked to specific patterns of heart...

Imperial College London's Center for Psychedelic Research is recruiting couples who plan to consume MDMA or other psychedelics in real-world settings for a study examining the effects on relationship intimacy, attachment and satisfaction. As DoubleBlind reported, the study will explore both the...

A recent placebo-controlled study published in Psychofarmacology offers promising findings for individuals using medicinal cannabis oil to treat insomnia. Led by Anastasia Suraev and colleagues, the research reveals that taking a single dose of medicinal cannabis oil before bed does not impair...

Firefly Neuroscience, Inc. (NASDAQ:AIFF) announced a collaboration with Bright Minds Biosciences Inc. (NASDAQ:DRUG) to analyze data from the first-in-human Phase 1 study of BMB-101, Bright Minds’ lead compound for neuropsychiatric disorders and refractory epilepsy. Firefly employed its...

Awakn Life Sciences Corp. (OTC:AWKNF), a clinical-stage biotechnology company, has announced a new partnership with the University of Nottingham to conduct in vivo testing of its aminoindane new chemical entity as part of its preclinical program. This research will explore the therapeutic potential...

Enveric Biosciences (NASDAQ:ENVB), a biotechnology company specializing in neuroplastogenic small-molecule therapeutics, revealed positive data from preclinical safety and pharmacology studies of its lead drug candidate, EB-003. The Massachusetts-based company announced that the results show the...

A new study conducted by Monash University researchers offers promising insights into how psilocybin, a compound found in magic mushrooms, may help treat major depression. As Medicalxpress reported, in a groundbreaking experiment, rats treated with psilocybin demonstrated increased optimism and...

A groundbreaking study conducted by researchers from Spain’s Universidad de las Palmas de Gran Canaria has shown that low-dose LSD may provide a safe and effective treatment for dogs suffering from anxiety. This independent study, published in Veterinary Research Communications, is the first...

A groundbreaking study from New York’s Columbia University suggests that psilocybin, the psychoactive compound in magic mushrooms may offer relief to individuals suffering from body dysmorphic disorder (BDD). The research, published in Psychedelics, explored the effects of psilocybin on brain...

Neuroplastogen biotech company Enveric Biosciences (NASDAQ:ENVB) has presented research highlighting its lead compound, EB-003 at the 7th Neuropsychiatric Drug Summit showing beneficial outcomes in preclinical models of anxiety and depression. EB-003 is a neuropathogenic and non-hallucinogenic N, N...